Cancer Biotherapy and Radiopharmaceuticals
Mary Ann Liebert Inc. · United States
Metrics
- Impact factor
- 1.7-0.4 Clarivate JCR
- WoS quartile
- Q3 Clarivate JCR, best category
- SJR
- 0.498Q2 SCImago
- h-index
- 55
- CAS tier
- Tier 4 Chinese Academy of Sciences
- Citations per paper
- 1.94 last 2 years
- Articles per year
- 100
- Self-citation
- 0%
- Fee (APC), est.
- $3,010 estimated, check the journal
About this journal
- ISSN
- 1084-9785 (print) · 1557-8852 (online)
- Publisher
- Mary Ann Liebert Inc.
- Country
- United States · Northern America
- Indexed in
- SCIE
- Access
- Hybrid · 7.7% gold OA
- Founded
- 1996
- Frequency
- Bimonthly
- Original research
- 100%
- Subject areas
- Biochemistry, Genetics and Molecular Biology, Medicine, Pharmacology, Toxicology and Pharmaceutics
- Categories
- Medicine, Radiology, Nuclear Medicine & Medical Imaging
- Common topics
- Medicine, Biology, Genetics, Internal medicine, Chemistry
Similar journals
- Q3WoS
Molecular and Cellular Biology
Impact factor 2.8h-index 308SJR 0.98 - Q3WoS
Journal of Cell Science
Impact factor 3.9h-index 252SJR 1.59 - Q3WoS
Biochemical and Biophysical Research Communications
Impact factor 2.5h-index 243SJR 0.72 - Q3WoS
Biochemistry
Impact factor 2.7h-index 231SJR 1.06 - Q3WoS
Molecular Microbiology
Impact factor 3.1h-index 226SJR 1.31 - Q3WoS
Molecular Biology of the Cell
Impact factor 3h-index 207SJR 1.44
Figures as of the last import; ranks are a guide, not a verdict. Back to all journals